SciSparc (SPRC) announced that its collaboration with Clearmind Medicine Inc. (CMND) has led to the publication of an international patent application under the Patent Cooperation Treaty, PCT. The patent application published under the European Patent Office covers an innovative combination therapy of Clearmind’s proprietary 5-methoxy-2-aminoindane and SciSparc’s Palmitoylethanolamide for the treatment of metabolic syndrome and obesity.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on SPRC:
- Clearmind announces publication of international patent application under PCT
- SciSparc Announces Patent Filing and Merger Updates
- Psychedelic: Filament reports compassionate use approval for psilocybin
- Clearmind Medicine, SciSparc filed new international patent application
- Clearmind Medicine files international patent application under PCT